<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04268108</url>
  </required_header>
  <id_info>
    <org_study_id>Liquid TIL</org_study_id>
    <nct_id>NCT04268108</nct_id>
  </id_info>
  <brief_title>L-TIL in Patients With Malignancy Resistance to Anti-PD-1 Therapy</brief_title>
  <official_title>Clinical Study of Liquid Tumor Infiltrating Lymphocytes in Patients With Advanced Malignancies Resistance to Anti-PD-1 Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henan Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety and effectiveness of liquid tumor infiltrating lymphocytes in patients with advanced
      malignant tumors who have failed to anti-PD-1 therapy
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2, 2020</start_date>
  <completion_date type="Anticipated">June 19, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 19, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>the rate of reverse events</measure>
    <time_frame>three months</time_frame>
    <description>the rate of reverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical benefit rate</measure>
    <time_frame>three months</time_frame>
    <description>the proportion of patients benefit from liquid tumor infiltrating lymphocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to progression</measure>
    <time_frame>six months</time_frame>
    <description>from the date of therapy to the first date of determined progressive disease</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>group 1</arm_group_label>
    <description>arm 1: secondary resistance to anti-PD-1 therapy: this patients group received liquid tumor infiltrating lymphocytes combined anti-PD-1 therapy.
arm 2: primary resistance to anti-PD-1 therapy: this patients group received FC preconditioning before received liquid tumor infiltrating lymphocytes</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>liquid tumor infiltrating lymphocytes</intervention_name>
    <description>Isolatation and amplification PD-1+ cells from peripheral blood lymphocytes under GMP conditions for clinical use.</description>
    <arm_group_label>group 1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Eligible patients in our hospital
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Expected lifespan is over 3 months

          -  malignant tumors diagnosed by pathological examination

          -  Imaging examination is at advanced stage with at least one measurable lesion

          -  Ineffective or resistant to previous anti-PD-1 therapy

          -  ECOG score 0-2

          -  Adequate organ function

          -  No other serious diseases that conflict with this protocol

          -  Women of childbearing age must check for a negative blood pregnancy test within 7
             days, and subjects of childbearing age must use appropriate contraception during the
             test and within 3 months

          -  witten informed consent from the patients

        Exclusion Criteria:

          -  Severe infectious disease within 4 weeks before enrollment

          -  Active hepatitis B or C virus or HIV infection

          -  Severe autoimmune disease or immunodeficiency disease

          -  Severe allergies

          -  Severe mental disorder

          -  Systematically used a large amount of glucocorticoids within 4 weeks before enrollment

          -  With severe heart, liver, kidney insufficiency, diabetes and other diseases

          -  Participation in other clinical studies in the past 3 months or having been treated
             with other gene products
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Quanli Gao, Dr.</last_name>
    <phone>+86-371-65587795</phone>
    <email>gaoquanli2015@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tiepeng Li, Dr.</last_name>
    <phone>+86-371-65587199</phone>
    <email>claylee5405@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Affiliated Cancer Hospital of Zhengzhou University &amp; Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quanli Gao, M.D</last_name>
      <phone>+86-371-65587795</phone>
      <email>gaoquanli2015@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Lingdi Zhao, M.D.</last_name>
      <phone>+86-371-65587483</phone>
      <email>lingdizhao@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 11, 2020</study_first_submitted>
  <study_first_submitted_qc>February 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2020</study_first_posted>
  <last_update_submitted>June 10, 2020</last_update_submitted>
  <last_update_submitted_qc>June 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>liquid tumor-infiltrating lymphocytes</keyword>
  <keyword>anti-PD-1</keyword>
  <keyword>resistance</keyword>
  <keyword>solid tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Need to solicit patients' consent whether to agree to share their information during the enrollment process,</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

